|
Human Genome Sciences (HGS) knows that the path to good health starts at the molecular level. Using its expertise in human genetics, the firm is working on therapies for infectious and autoimmune diseases and cancer. One of its lead candidates is Albuferon, a long-acting version of protein therapy interferon alpha, that it is developing with Novartis to treat hepatitis C. Monoclonal antibody LymphoStat-B is also in later stages of clinical testing; GlaxoSmithKline is HGS' partner on the drug. With funding from the US government, HGS is developing an antibody that fights anthrax infection, and it has several anticancer antibodies at earlier stages of development.
|
| | | Contact Information | |
Address: |
14200 Shady Grove Road
Rockville, MD 20850-7464
| | Phone: | 301-309-8504 | | Fax: | 301-309-8512 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 48.40 M | | Revenue Growth (1 yr): | 15.70% | | Employees (2008): | 880 | | Employee Growth (1 yr): | 3.50% |
|
|
Key People
| | • |
Chairman:
Argeris N. (Jerry) Karabelas
| | • |
President, CEO, and Director:
H. Thomas (Tom) Watkins
| | • |
SVP Operations:
Curran M. Simpson
|
|
|
